

Title (en)  
A PHARMACEUTICAL MICRONUTRIENT COMPOSITION AND ITS USE TO SIMULTANEOUSLY INHIBIT MULTIPLE CELLULAR MECHANISMS OF INFECTIVITY CAUSED BY CORONAVIRUS, ITS VARIANTS AND MUTANTS

Title (de)  
PHARMAZEUTISCHE MIKRONÄHRSTOFFZUSAMMENSETZUNG UND IHRE VERWENDUNG ZUM GLEICHZEITIGEN HEMMEN MEHRERER ZELLULÄRER INFektionsMECHANISMEN, DIE DURCH CORONAVIRUS, SEINE VARIANTEN UND MUTANTEN VERURSACHT WERDEN

Title (fr)  
COMPOSITION PHARMACEUTIQUE DE MICRONUTRIMENTS ET SON UTILISATION POUR INHIBER SIMULTANÉMENT DE MULTIPLES MÉCANISMES CELLULAIRES D'INFECTIVITÉ PROVOQUÉS PAR UN CORONAVIRUS, SES VARIANTES ET MUTANTS

Publication  
**EP 4064861 A1 20221005 (EN)**

Application  
**EP 21801817 A 20210325**

Priority  
• US 202163149633 P 20210215  
• US 2021024182 W 20210325

IPC 8 full level  
**A23L 33/10** (2016.01); **A23L 33/105** (2016.01); **A23L 33/12** (2016.01); **A23L 33/15** (2016.01)

CPC (source: EP)  
**A61K 31/05** (2013.01); **A61K 31/12** (2013.01); **A61K 31/198** (2013.01); **A61K 31/352** (2013.01); **A61K 31/366** (2013.01); **A61K 31/375** (2013.01); **A61K 31/7048** (2013.01); **A61K 36/31** (2013.01); **A61K 36/82** (2013.01); **A61K 36/9066** (2013.01); **A61P 31/12** (2017.12); **A61P 31/14** (2017.12)

C-Set (source: EP)  
1. **A61K 36/31 + A61K 2300/00**  
2. **A61K 31/7048 + A61K 2300/00**  
3. **A61K 36/82 + A61K 2300/00**  
4. **A61K 36/9066 + A61K 2300/00**  
5. **A61K 31/375 + A61K 2300/00**  
6. **A61K 31/12 + A61K 2300/00**  
7. **A61K 31/366 + A61K 2300/00**  
8. **A61K 31/352 + A61K 2300/00**  
9. **A61K 31/198 + A61K 2300/00**  
10. **A61K 31/05 + A61K 2300/00**

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

DOCDB simple family (publication)  
**DE 212021000181 U1 20220111**; EP 4064861 A1 20221005; EP 4064861 A4 20231018

DOCDB simple family (application)  
**DE 212021000181 U 20210325**; EP 21801817 A 20210325